Abstract
Targeted recruitment of E3 ubiquitin ligases to degrade traditionally undruggable proteins is a disruptive paradigm for developing new therapeutics. Two salient limitations are that <2% of the ~600 E3 ligases in the human genome have been exploited to produce proteolysis targeting chimeras (PROTACs), and the efficacy of the approach has not been demonstrated for a vital class of complex multi-subunit membrane proteins- ion channels. NEDD4-1 and NEDD4-2 are physiological regulators of myriad ion channels, and belong to the 28-member HECT (homologous to E6AP C-terminus) family of E3 ligases with widespread roles in cell/developmental biology and diverse diseases including various cancers, immunological and neurological disorders, and chronic pain. The potential efficacy of HECT E3 ligases for targeted protein degradation is unexplored, constrained by a lack of appropriate binders, and uncertain due to their complex regulation by layered intra-molecular and posttranslational mechanisms. Here, we identified a nanobody that binds with high affinity and specificity to a unique site on the N-lobe of the NEDD4-2 HECT domain at a location physically separate from sites critical for catalysis- the E2 binding site, the catalytic cysteine, and the ubiquitin exosite- as revealed by a 3.1 Å cryo-electron microscopy reconstruction. Recruiting endogenous NEDD4-2 to diverse ion channel proteins (KCNQ1, ENaC, and Ca<sub>V</sub>2.2) using a divalent (DiVa) nanobody format strongly reduced their functional expression with minimal off-target effects as assessed by global proteomics, compared to simple NEDD4-2 overexpression. The results establish utility of a HECT E3 ligase for targeted protein downregulation, validate a class of complex multi-subunit membrane proteins as susceptible to this modality, and introduce endogenous E3 ligase recruitment with DiVa nanobodies as a general method to generate novel genetically-encoded ion channel inhibitors.
Introduction
Ion channels function as the biological equivalent of transistors, governing essential physiological processes ranging from cardiac rhythm to neuronal signaling. Their fundamental role makes them prime therapeutic targets for conditions such as arrhythmias, epilepsy, and chronic pain. However, achieving high selectivity remains a significant hurdle; traditional small-molecule blockers often struggle to distinguish between closely related channel subtypes, leading to unwanted side effects.
Targeted Protein Degradation (TPD) has emerged as a transformative strategy to address "undruggable" targets. By redirecting the cell's internal disposal machinery—the ubiquitin-proteasome system—TPD tools like PROTACs can eliminate specific proteins rather than merely inhibiting them. Despite its potential, TPD has seen limited application for complex, multi-subunit membrane proteins like ion channels. Furthermore, the field has largely ignored the HECT (homologous to E6AP C-terminus) family of E3 ligases, which are the natural regulators of these channels, because their complex internal regulation makes them difficult to control.
The DiVa Platform: A Divalent Nanobody Approach
In a recent study published by Morgenstern et al. from Columbia University, researchers introduced the Divalent nanobody (DiVa) platform. This system acts as a molecular bridge to recruit the endogenous E3 ligase NEDD4-2 to specific ion channel targets.
The platform relies on a high-affinity nanobody, nb.C11, discovered through yeast display libraries. Using 3.1 Å cryo-electron microscopy (cryo-EM), the team demonstrated that nb.C11 binds to a unique "sweet spot" on the N-lobe of the NEDD4-2 HECT domain. Crucially, this binding site is physically distinct from the catalytic cysteine, the E2 binding site, and the ubiquitin exosite, ensuring that the nanobody does not interfere with the ligase's enzymatic function.
By fusing nb.C11 to a second nanobody specific to a target ion channel (such as KCNQ1, ENaC, or $Ca_V2.2$), the researchers created a divalent construct that forces the proximity of the ligase and its new substrate, marking the channel for removal from the cell surface.
Results and Specificity
The DiVa approach demonstrated remarkable efficacy and precision across several experimental models:
- Potent Functional Inhibition: Recruitment of endogenous NEDD4-2 led to a 70-80% reduction in ionic currents for KCNQ1, ENaC, and $Ca_V2.2$ as measured by patch-clamp recordings.
- Superior Selectivity: One of the most significant advantages of the DiVa system is its specificity. Global TMT-multiplexed proteomics revealed that while traditional overexpression of NEDD4-2 perturbed nearly 800 proteins, the DiVa approach significantly affected only 18 proteins. This highlights the benefit of hijacking endogenous ligases rather than flooding the cell with exogenous enzymes.
- Disease Relevance: The researchers applied the DiVa system to a model of Liddle syndrome, a hereditary form of hypertension caused by mutations that prevent ENaC inhibition. The DiVa successfully restored control over the overactive sodium channels.
- Native Environment Efficacy: The system remained effective in primary mouse dorsal root ganglion (DRG) neurons, successfully inhibiting native calcium currents in a complex biological environment.
Discussion and Future Directions
The study provides the first definitive proof that HECT-family E3 ligases can be effectively harnessed for targeted protein degradation. By validating that complex membrane proteins are susceptible to this modality, the authors have opened a new avenue for drug development.
While the current implementation requires genetic delivery, the modular nature of the DiVa platform suggests it could be adapted for other membrane proteins, including transporters and G protein-coupled receptors (GPCRs). Future research will likely focus on developing small-molecule or mRNA-based delivery systems to transition this technology from a powerful research tool into a clinical therapeutic.
Summary updated